Branded PPI denied as non-formulary by Aetna?

Aetna's specific coverage criteria for branded ppi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Branded PPIs as Non-Formulary

Aetna's formulary places most branded proton pump inhibitors on a non-preferred or excluded tier because multiple generic PPIs are considered clinically interchangeable for the majority of patients. A non-formulary denial does not mean the drug is never covered — it means you must demonstrate a medically necessary reason the formulary alternatives are inadequate for you specifically. This type of denial has a meaningful appeal success rate when the prescriber provides targeted documentation.

## Federal Appeal Rights

Under ACA §2719, you have the right to a formal internal appeal and then independent external review by an IRO if the internal appeal fails. ERISA-governed plans carry equivalent protections under ERISA §503. The external-review window is typically four months from the date of the final internal denial letter — calendar that deadline immediately. Expedited external review is available when delay poses a serious health risk.

## Appeal Process and Timeline

1. Obtain Aetna's formulary exception criteria from the denial letter or the plan's Summary of Benefits and Coverage. 2. Request a formulary exception through the internal appeals process, which for pre-service denials must be decided within 30 days. 3. Escalate to the Member Appeals process if the exception is denied, then to external review if the internal appeal is upheld. 4. Track every submission date; plans are bound by regulatory response deadlines.

## Documentation to Gather

• Formulary alternative trial history: for each formulary generic PPI, document the dates of use, clinical response, and reason for discontinuation (inadequate control, adverse reaction, inactive-ingredient intolerance).
• Diagnostic records: confirm the underlying condition requiring PPI therapy (e.g., erosive esophagitis grade, Barrett's surveillance, peptic ulcer documentation).
• Adverse effect or intolerance records: pharmacy dispensing records, clinic notes recording the adverse event, and any allergy or intolerance flags in the chart.
• Prescriber letter of medical necessity: a statement that formulary alternatives have been trialed and failed, or are contraindicated, with reference to the FDA prescribing label of the requested branded product.

## Criteria-Mapping Strategy

Pull Aetna's current Pharmacy Clinical Policy for PPI formulary exceptions and the FDA-approved label for the branded PPI. For each exception criterion listed, document your patient's specific chart evidence that meets it. A formulary exception appeal is strongest when it reads less like a general advocacy letter and more like a clinical checklist — every requirement answered with a date, a note, and an outcome.